AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25516006
Drug: Ibuprofen/Famotidine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/Famotidine combination
Trial: 17048576
Drug: Integrative traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative traditional Chinese and Western medicine (ICWM) - Fufang Huangqi granule and lamivudine for at least 24 weeks
Trial: 17048576
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) - Fufang Huangqi granule for at least 24 weeks
Trial: 11113832
Drug: Outreach program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outreach program for young children with cerebral palsy (monthly training of parents with pictorial guidance manual)
Trial: 11113832
Drug: Center-based mother-child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Center-based mother-child group (daily attendance)
Trial: 8459913
Drug: Gadodiamide injection
RxNorm normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadodiamide injection (Gd-DTPA BMA), dosage: 0.1 mmol/kg body weight (0.2 ml/kg)
Trial: 8459913
Drug: Gadopentetate dimeglumine
RxNorm normalized name: Gadopentetate Dimeglumine
DrugBank: Gadopentetic acid (DB00789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadopentetate dimeglumine (Gd-DTPA), dosage: 0.1 mmol/kg body weight (0.2 ml/kg)
Trial: 29035068
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard therapy sessions)
Trial: 9087484
Drug: dideoxyinosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dideoxyinosine (ddI) monotherapy
Trial: 3512382
Drug: Tripotassium dicitrato
RxNorm normalized name: Tripotassium dicitratobismuthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitrato bismuthate (TDB) tablets
Trial: 31856902
Drug: Treatment guided
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment guided by cerebral oxygenation monitoring
Trial: 22986440
Drug: linaclotide 290
RxNorm normalized name: LINACLOTIDE 290MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linaclotide 290 μg oral once daily
Trial: 18720044
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (600 mg) followed by oral iron sulphate (200 mg daily from week 5)
Trial: 18720044
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron sulphate (200 mg daily)
Trial: 15932366
Drug: Trefoil factor
RxNorm normalized name: Trefoil Factor 2
DrugBank: Trefoil Factor 2 (DB15750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trefoil factor family‐3 enema (10 mg/mL)
Trial: 10583036
Drug: Perindopril 4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4-8 mg once daily
Trial: 30791771
Drug: Linaclotide (72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linaclotide (72 µg, 145 µg, 290 µg)
Trial: 27354646
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus Cisplatin (DP) - Docetaxel 70 mg/m²; Cisplatin 60 mg/m²; administered every 28 days
Trial: 25065090
Drug: Kegel exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kegel exercise with concentration therapy
Trial: 23247938
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg/wk
Trial: 23247938
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every other week (EOW)
Trial: 19430082
Drug: Daily iron-folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily iron-folate (IFA) supplementation (100 mg elemental iron + 0.5 mg folic acid daily for one year)
Trial: 19430082
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly iron-folate (IFA) supplementation (100 mg elemental iron + 0.5 mg folic acid twice weekly for one year)
Trial: 19430082
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly iron-folate (IFA) supplementation (100 mg elemental iron + 0.5 mg folic acid once weekly for one year)
Trial: 12502652
Drug: HS glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS glucose >10 mmol/l
Trial: 10475722
Drug: Thioridazine (Y:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (Y: 50 mg; O: 25 mg)
Trial: 10475722
Drug: Remoxipride (Y:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (Y: 100 mg; O: 50 mg)
Trial: 7104167
Drug: Drug with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug with non-linear release (NLR)
Trial: 7104167
Drug: Drug with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug with linear release (LR)
Trial: 7104167
Drug: Drug-free control
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free control
Trial: 31825466
Drug: Mirtazapine 30
RxNorm normalized name: mirtazapine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30 mg orally once daily for 24 weeks
Trial: 30726969
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg before oral glucose test
Trial: 30726969
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg before and during metabolic study
Trial: 27821724
Drug: Autologous CD34+
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous CD34+ cells (minimum 10 mol/L±20% cells), N=78
Trial: 21601248
Drug: Tamsulosin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin plus solifenacin 2.5 mg (TAM+SOL)
Trial: 21601248
Drug: Tamsulosin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin plus solifenacin 5 mg (TAM+SOL)
Trial: 16236919
Drug: Smoking reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking reduction with nicotine replacement therapy (nicotine gum and patch), required to reduce smoking by 25% for 2 weeks, 50% for 2 weeks, and 75% during the final 2 weeks.
Trial: 8740120
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily for 3-5 days)
Trial: 1833892
Drug: Enoximone 3
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 3 mg/kg orally
Trial: 7042179
Drug: Pre‐operative radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐operative radiotherapy combined with daily intravenous fluorouracil during the first 4 days of irradiation followed by surgery (C)
Trial: 15558726
Drug: Experimental vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental vaginal gel
Trial: 15114295
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment with 40 mg of ZnSO4 in a single dose
Trial: 15114295
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with 100 mg ZnSO4 in a single dose daily for 7 days
Trial: 23237616
Drug: Culturally and
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally and family tailored interventions to manage asthma symptoms; specific dosage and duration not applicable as this is qualitative data.
Trial: 21036617
Drug: Stripping of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stripping of the posterior knee capsule (PCS)
Trial: 21036617
Drug: No stripping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No stripping of the posterior knee capsule (no-PCS)
Trial: 17695792
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri Tablets (active treatment for 4 weeks)
Trial: 17695792
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri Tablets (active treatment for 8 weeks)
Trial: 15217515
Drug: Lymphatic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphatic chemotherapy (LC) - subcutaneous injection of 4 ml of carboplatin-activated carbon suspension (20 mg of carboplatin)
Trial: 15217515
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (VC) - intravenous administration of 20 mg of aqueous carboplatin
Trial: 11231856
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (500 mg of methylprednisolone administered intravenously 2 hours before surgery)
Trial: 9670258
Drug: Intraoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiotherapy (IORT) plus external beam radiotherapy (EBRT) with concomitant chemotherapy (5-FU, leucovorin)
Trial: 7758398
Drug: L-carnitine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (4 g or 2 g) with 10% or 5% glucose infusion
Trial: 7758398
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10% or 5% glucose infusion without L-carnitine)
Trial: 2455778
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with vinblastine for 6 months
Trial: 2455778
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (cisplatin, vinblastine, and bleomycin)
Trial: 30799192
Drug: Serum albumin
RxNorm normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum albumin levels <51.4 g/L
Trial: 30799192
Drug: Serum albumin
RxNorm normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum albumin levels ≥51.4 g/L
Trial: 30799192
Drug: Serum albumin
RxNorm normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum albumin levels <51.4 g/L without proteinuria
Trial: 19441668
Drug: Escitalopram (n=51,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (n=51, 10-20 mg/day)
Trial: 19441668
Drug: Nortriptyline (n=39,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (n=39, 75-150 mg/day)
Trial: 14728846
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin and compound cyproterone acetate (CPA) (group A3)
Trial: 14728846
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (group A2)
Trial: 14728846
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin and CPA (group A3)
Trial: 10775075
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) therapy
Trial: 8839730
Drug: Reformulated Oka
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated Oka strain varicella vaccine
Trial: 6695658
Drug: Verapamil, 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil, 7.5 mg intravenously
Trial: 30037480
Drug: Reminder letters
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reminder letters sent to parents or guardians of eligible adolescents due for the first dose of HPV vaccine.
Trial: 24905296
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg daily for 6 months
Trial: 22920048
Drug: Olmesartan medoxomil/hydrochlorothiazide
RxNorm normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40 mg/25 mg
Trial: 22920048
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM) 20 mg daily to OM 40 mg
Trial: 17602170
Drug: Blueberry/apple juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry/apple juice providing 97 mg quercetin and 16 mg ascorbic acid a day
Trial: 15074091
Drug: Pushen capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pushen capsule (PSC) (4 capsules, tid)
Trial: 15074091
Drug: Zhibituo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhibituo tablet (3 tablets, tid)
Trial: 11677003
Drug: Gabapentin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1200 mg, administered three times daily for 12 months)
Trial: 334220
Drug: Nomifensine 50
RxNorm normalized name: nomifensine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine 50 mg
Trial: 30606789
Drug: Warfarin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (18 months treatment after initial 6 months)
Trial: 30606789
Drug: Placebo (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (18 months treatment after initial 6 months)
Trial: 30606789
Drug: Warfarin (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (42 months total follow-up)
Trial: 24613094
Drug: Estradiol ≥30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol ≥30 ng/mL with percent mean body weight
Trial: 1980415
Drug: Promazin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promazin (1.0 mg/kg)
Trial: 1980415
Drug: Promethazin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazin (1.0 mg/kg)
Trial: 1980415
Drug: Chlorphenaethazin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorphenaethazin (1.0 mg/kg)
Trial: 6992760
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment factors (sex, social class, optimism about therapist)
Trial: 6992760
Drug: Degree of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degree of improvement during treatment
Trial: 25328079
Drug: Sitagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (50 mg)
Trial: 25328079
Drug: Metformin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (750 mg)
Trial: 24942407
Drug: Cilostazol (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100mg twice daily)
Trial: 21147691
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) 4 mg intravenous every 3 months
Trial: 17991545
Drug: Bicalutamide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (150 mg/day for 120 days) plus surgery
Trial: 16296363
Drug: Midazolam 0.04‐0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.04‐0.05 mg x kg(‐1)
Trial: 11911994
Drug: Glyceryltrinitrate (GTN)
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyceryltrinitrate (GTN) + Capsaicin cream
Trial: 11911994
Drug: Capsaicin cream
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin cream alone
Trial: 31160237
Drug: Carfilzomib (56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (56 mg/m2) and Dexamethasone (Kd56)
Trial: 28973620
Drug: Clinically guided
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically guided warfarin dosing
Trial: 23537721
Drug: rIX-FP (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIX-FP (25 IU/kg) on-demand therapy for 20 weeks
Trial: 23537721
Drug: rIX-FP (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIX-FP (25 IU/kg) weekly prophylaxis for up to 44 weeks
Trial: 19950570
Drug: TAM sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAM sequential (TAM_SEQ)
Trial: 19950570
Drug: TAM concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAM concurrent (TAM_CON)
Trial: 19950570
Drug: AI sequential
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI sequential (AI_SEQ)
Trial: 19950570
Drug: AI concurrent
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI concurrent (AI_CON)
Trial: 17300863
Drug: Interferon-beta(1a) (Rebif,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta(1a) (Rebif, Serono) subcutaneous injections three times a week (group A)
Trial: 17300863
Drug: Not receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not receiving disease-modifying treatment (group B)
Trial: 8857018
Drug: Interleukin-2 plus
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2 plus antiretroviral therapy
Trial: 1298048
Drug: Repeated injections
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated injections of ranitidine, 50 mg every 6 h (group A)
Trial: 1298048
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ranitidine, 50-mg bolus followed by 0.125 mg/kg/h (group B)
Trial: 6326014
Drug: Lonidamine in
RxNorm normalized name: lonidamine
DrugBank: Lonidamine (DB06266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lonidamine in combination with other anticancer agents
Trial: 31145689
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg) with piperine (5 mg)
Trial: 18488813
Drug: Adcef Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adcef Suspension (125 mg/5 ml cefdinir)
Trial: 18488813
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (125 mg/5 ml cefdinir)
Trial: 17109346
Drug: Attenuated rotavirus
RxNorm normalized name: Live attenuated Rotavirus Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated rotavirus vaccine candidate 89-12
Trial: 17109346
Drug: Rotarix vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotarix vaccine developed from attenuated 89-12
Trial: 15235312
Drug: Valtrex treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valtrex treatment
Trial: 11765590
Drug: lysine clonixinate
RxNorm normalized name: lysine clonixinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lysine clonixinate (125 mg five times a day for 3 days before and 13 days after ingestion of a single dose of phenprocoumon)
Trial: 11765590
Drug: phenprocoumon (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenprocoumon (18 mg)
Trial: 29436564
Drug: Celery leaf
RxNorm normalized name: CELERY LEAF PWDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celery leaf extract (250 mg, 3 times per day for 12 days)
Trial: 23389964
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for OCD
Trial: 20613468
Drug: Propofol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (6 microg/ml) via plasma target‐controlled infusion using the Schnider model
Trial: 16704094
Drug: 1.1% sodium
RxNorm normalized name: Neutral 1.1% Sodium Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1% sodium fluoride and acidulated phosphate gel
Trial: 26004421
Drug: CIRCuiTS (Computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIRCuiTS (Computerized Cognitive Remediation Therapy Programme)
Trial: 22759830
Drug: Autologous platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet-rich plasma eyedrops along with standard medical treatment
Trial: 20096936
Drug: Olanzapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (15 mg QD on day 1, 5-20mg QD thereafter)
Trial: 12558710
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) rehydration
Trial: 12558710
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) rehydration